Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier

*Mayumi Komine, Jin Meijuan, Miho Kimura-Sashikawa, Razib MD. Hossain, Tuba M. Ansary, Tomoyuki Oshio, Jitlada Meephansan, Hidetoshi Tsuda, Shin-ichi Tominaga and Mamitaro Ohtsuki*

### **Abstract**

Keratinocytes are the major structural component of the epidermis. They differentiate from the basal through spinous to granular layers, and abrupt loss of nucleus pushes them to differentiate into cornified layers, which exfoliates as scales. Differentiation process is tightly controlled by the organized expression of transcription factors and other regulators, which sustains the physiological function of the skin barrier. The genetic abnormality of the molecules expressed in this pathway causes hereditary skin disorders and defects in barrier function. Ichthyosis is caused by keratins, enzymes, and structural proteins involved in lipid metabolism and cornified envelope formation. Atopic dermatitis seemed to be an immune-oriented disease, but the recent finding revealed filaggrin as a causative factor. Keratinocytes respond to acute injury by releasing alarmins. IL-33 is one of such alarmins, which provoke Th2-type inflammation. IL-33 works as a cytokine and, at the same time, as nuclear protein. IL-33 has double-faced nature, with pro- and anti-inflammatory functions. Epidermis, covering the entire body, should stay silent at minor insults, while it should provoke inflammatory signals at emergency. IL-33 and other doublefaced molecules may play a role in fine tuning the complexed function of epidermal keratinocytes to maintain the homeostasis of human body.

**Keywords:** keratinocytes, keratin, mutation, ichthyosis, hereditary skin disorders

### **1. Introduction**

Keratinocytes are the principal epidermal cells constituting the outermost layer of the skin—the external and largest organ of the human body. They are immunologically active in that they produce various cytokines and chemokines, stimulating dendritic cells and lymphocytes to trigger inflammatory skin diseases, as well as they respond to cytokines produced from immune cells to establish skin lesions of inflammatory skin diseases, such as psoriasis and atopic dermatitis. They are also very efficient in avoiding harsh environmental assaults, such as chemical, mechanical, radiological, and microbial insults. The keratinocytes protect the dermal homeostasis by having a constant turnover whereby the basal (inner) layer differentiates into the cornified (outer) layer. Thus, they form a constant and perfect outer barrier to the inner dermal layers and the body. They also form a rigid mechanical barrier by cornification—constructing a brick-and-mortar type of structure with cornified cells and lipids, the defects in either of which cause hereditary skin disorders upon mutation. They also secrete various antimicrobial peptides, such as cathelicidin, psoriasin, defensin, and many S100 proteins, to protect the skin from infection. The nuclei of keratinocytes contain various alarmins, such as HMGB1, IL-33, and IL-1alpha, which can induce rapid and strong inflammation upon injury, but also can get promptly inactivated by the enzymes present in the inflammatory environment. However, malfunctioning of the keratinocytes at its immunological level or at a genetic/protein level can lead to pathological conditions such as psoriasis, atopic dermatitis, and hereditary skin disorders.

Keratinocytes, as the main component of outermost epidermal layer, should provoke and at the same time stop inflammation at appropriate time points to maintain a stable and healthy condition of not only the skin, but also the entire body. Keratinocytes harbor anti-inflammatory properties more than other types of cells do, such as lymphocytes, macrophages, and dendritic cells, as keratinocytes are always exposed to environmental insults. The mechanism of developing inflammatory conditions has been intensely investigated; however, the mechanism of ceasing inflammation has not been fully investigated. I speculate that a novel approach to maintaining healthy conditions would be unraveled when the mechanism of sequestrating inflammation is investigated and that epidermal keratinocytes are good candidates to investigate these mechanisms because they present pro- and anti-inflammatory properties in vivo and in vitro.

In this chapter, various cutaneous disorders have been discussed with emphasis on keratinocyte function and roles in pathogenesis. We have surveyed PubMed with each disease name, picked up the original literature with pivotal findings, reviewed articles covering the related area of interest, and wrote this chapter.

### **2. Epidermal keratinocytes**

Epidermal keratinocytes form a stratified epithelium, consisting of basal, spinous, granular, and cornified layers starting from the dermal side. Epidermal keratinocytes exert their functions through structural components such as actin, microtubules, keratin filaments, desmosomes, hemidesmosomes, tight junctions, and adherence junctions; their motility, proliferation, and cytokine production being controlled by these structural proteins. Epidermal keratinocytes gradually differentiate through the layers—from the basal, spinous, and granular, ultimately to the cornified cell layer. They demonstrate various characteristic features owing to their differential function and according to their differentiation state, which are sometimes more complex than those of simple epithelial cells constituting the digestive tract and glands [1].

The primary and most important function of epidermal keratinocytes is their role as a physical barrier of the skin, in addition to their role as a responder to the external stimuli. The cornified cells, together with inter-cornified cell lipids, form cornified cell barriers to protect the inner body from harsh external environmental stimuli. The cornified cells, upon catalysis by transglutaminase 1, form a cornified cell envelope—a strong structure composed of filaggrin that aggregates keratin filaments, with various protein components such as involucrin, loricrin, SPR, and desmosomal proteins. Defects in the enzymes and protein components essential in

*Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

forming cornified cell envelopes cause skin barrier dysfunction, resulting in skin disorders [2, 3].

Recent findings have revealed that some patients with atopic dermatitis (AD) harbor loss-of-function mutations in the filaggrin gene, resulting in severe skin barrier defects. Ichthyosis vulgaris (IV) is also caused by mutations in the filaggrin gene, but patients with this mutation develop either AD, IV, or both, indicating that mutations in the filaggrin gene alone are not enough to determine the phenotypes [4–7]. Mutations in the transglutaminase 1 gene and other genes important in the cornification processes, such as ATP-binding cassette subfamily A member 12 (ABCA12), and arachidonate 12-lipoxygenase 12 s type (ALOX12), cause hereditary ichthyosis, also known as acquired recessive congenital ichthyosis [8]. Connexin is a component of the gap junction, and mutation in gap junction protein beta 3 (GJB3) gene, which encodes connexin (Cx31) causes erythrokeratodermia variabilis, in which inflammatory erythematous eruptions with hyperkeratinization gradually changes its form [9]. Mutations in the loricrin gene cause loricrin keratoderma, with characteristic finger constriction ring formation or congenital ichthyosiform erythroderma [10, 11].

Steroid sulfatase is an enzyme that catalyzes the degradation of cholesterol sulfate, a molecule that functions in the attachment of cornified cells. The mutation in its gene causes X-lined ichthyosis, with retarded detachment of cornified cells, termed as retention hyperkeratosis. Point mutations result in typical skin manifestations; whereas, mutations spanning bigger lengths of this gene involving the surrounding genomic region are accompanied by other syndromic symptoms, such as mental retardation, short stature, and epilepsy [12].

### **Figure 1.**

*Characteristic skin manifestation in hereditary skin disorders with mutation in genes expressed in keratinocytes. a) Bulla formation on the foot of a child having epidermolysis bullosa simplex (EBS) and with mutation in the KRT5 gene. b) Macular brownish pigmentation in EBS with mottled pigmentation in patients with mutation in KRT5 gene. c) Hyperkeratosis in hands, d) nail deformity and e) dental decay in patients with dystrophic EB and with mutation in the integrin beta 4 gene. f) Diffuse hyperkeratosis in hands, with lichenification in wrist, g) hyperkeratosis with lichenification in cubital fossa, h) small bulla formation on diffuse erythema and i) its histopathology with hematoxylin and eosin staining in patients with Epidermolytic hyperkeratosis and mutation in KRT1 gene.*

### **Figure 2.**

*Characteristic skin manifestation and electron microscopic findings of genetic skin disorders. a) Clinical manifestation of X-liked ichthyosis (XI) patient, b) histopathology with hematoxylin and eosin staining, c) electron microscopic features in patients with XI and deletion in STS gene. d) Clinical manifestation of autosomal dominant type dystrophic EB (AD-DEB) patient, e) electron microscopy of skin sample from AD-DEB patient with heterozygous mutation in collagen type VII (COL7). f) Clinical manifestation of autosomal recessive type dystrophic EB patient, g) electron microscopy of skin sample AR-DEB patient with homozygous mutation in COL7.*



*Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

### **Table 1.**

*Representative non-syndromic and syndromic ichthyosis with causative genes. Modified citation from Ref. [3].*

Some hereditary keratinizing disorders are accompanied by syndromic symptoms other than skin manifestations. Mutations in GJB2 gene, encoding Cx26, cause KID syndrome—with keratitis, ichthyosis, and deafness as triads, exhibiting papillomatous and spinous keratotic eruptions on the face and extremities, and with palmoplantar keratoderma and alopecia [13]. Mutation in the serine protease inhibitor SPINK5 causes Netherton syndrome, with atopic dermatitis-like skin eruptions, characteristic ichthyosis linearis circumflexa and bamboo hair [14]. Sjogren-Larsson syndrome is caused by a mutation in the fatty aldehyde dehydrogenase (ALDH3A2) gene, with clinical symptoms including ichthyosis, spastic limb paralysis, and mental retardation [15]. **Figures 1** and **2** shows skin manifestations of several hereditary skin disorders. **Table 1** shows a summary of the types of ichthyosis and their accompanying gene mutations.

### **3. Keratinopathies**

Keratins are the main intermediate filaments of epidermal keratinocytes. The keratin family consists of more than 50 members; acidic keratin and basic keratin monomers pair to form heterodimers, which are then organized into tetramers with an anti-parallel alignment. Tetramers of keratins are stored at the peripheral boundaries of cells for filament formation when needed. Lateral and longitudinal aggregations of these tetramers and octamers form keratin filaments. Local pH, osmotic conditions, and phosphorylation status are thought to be the driving forces of filament formation [16].

Simple epithelia consist of simple epithelial keratins, such as K8, K18, and K19. Basal cells of the simple and stratified epithelia express K5 and K14, while the suprabasal cells express K1 and K10 in the interfollicular epidermis, K3 and K12 in the corneal epithelium, K4 and K13 in the esophageal epithelium, and K6 and K16 in the oral epithelium. The follicular epidermis and palmoplantar epidermis express K6, K16, and K17. Their expression is tightly controlled by transcription factors in a differentiation- and localization-dependent manner.

Mutations in keratin genes cause various hereditary skin disorders [17]. Mutations either in *KRT5* and *KRT14* gene cause epidermolysis bullosa simplex (EBS), manifested by bulla formation with slight mechanical forces from childhood. *KRT1* or *KRT10* gene mutations cause epidermolytic ichthyosis (EI), with characteristic histopathological features called epidermolytic hyperkeratosis characterized by large droplets of keratohyalin granules with vacuolization and hyperkeratosis in epidermal keratinocytes. A similar mutation in the *KRT9* gene causes Voerner-type palmoplantar keratoderma (PPK), with similar epidermolytic hyperkeratosis on the palm and soles, owing to the exclusive *KRT9* expression and distribution on palms and soles in humans. Similarly, a mutation in the *KRT2e*, expression of which is distributed in the granular layer of the epidermis, causes superficial epidermolytic ichthyosis. Pachyonychia congenita, manifested by thickening of finger and toenails and sometimes accompanying steatocystoma

multiplex, is caused by mutations in *KRT6*, *KRT16*, or *KRT17*, which is expressed in nails and follicular epithelium [18]. White sponge nevus usually seen in the oral epithelium is caused by mutations in the *KRT4* or *KRT13* gene, with whitish, somewhat keratinized oral epithelium showing papillomatous growth [19]. Simple epithelial keratins, such as *KRT7*, *KRT8*, *KRT18*, and *KRT19*, are distributed not only in cutaneous glandular structures, such as sweat glands and sebaceous glands but also in various internal organs, including the digestive tract and liver. Mutations of these simple epithelial keratins in skin disorders have not yet been elucidated, but the importance of *KRT8* and *KRT18* mutations in liver diseases have been postulated. End-stage liver disease patients have been reported to show higher rates of *KRT 8/18* mutations [20]. The solubility of keratins depends on their phosphorylation status, and mutations in the phosphorylation site affect the solubility of keratin filaments, resulting in cell damage. Recent findings revealed that the phosphorylation of keratins is also affected by the acetylation or methylation status of keratins; thus, mutations at these sites also cause cell damage. Mutations in *KRT8* and *KRT18* affect the keratin phosphorylation, acetylation, or methylation, in turn, affecting the stability in keratin filaments, resulting in an imbalance between *KRT8* and *KRT18* proteins, and causing excessive oxidative stress and susceptibility to liver disorders [21, 22].

### **4. Adherence machinery of epidermal keratinocytes**

Adherence machinery is indispensable for controlling keratinocyte cell motility, proliferation, and viability, as well as the epidermal barrier function by controlling cell attachment and cell tension. Keratinocytes have six major adherence mechanisms [23, 24]: 1) Hemidesmosomes, which connect basal keratinocytes to the dermal component, with cytoskeletal molecules such as keratins, 2) desmosomes, which connect neighboring keratinocytes, sustain the epidermal sheet structure and maintain tension by connecting to cytoskeletal molecules, such as keratins, 3) Adherence junctions, which control keratinocyte motility by connecting intracellular actin to E-cadherin in the adherence junctions to neighboring keratinocytes [25], 4) Gap junctions, which also have ion-transporter functions, indirectly control keratinocyte barrier function, 5) Tight junctions, which control the liquid interface in epithelia and consist of claudins and occludins [26], and 6) Focal adhesion—attachment of plaques connecting cells to the extracellular matrix, thereby, making connections to scaffolds to maintain the keratinocyte motility, proliferation, and viability.

Hemidesmosomal proteins are indispensable for maintaining normal dermalepidermal structures (**Figure 3**) [27, 28]. Mutations in hemidesmosomal protein genes, such as integrin alpha 6 or beta 4, cause junctional epidermolysis bullosa [29]. Mutations in plectin, a constituent of desmosomes and hemidesmosomes, cause junctional type epidermolysis bullosa with pyloric atresia [30]. Collagen type VII localizes from just beneath lamina densa to support attachment of lamina densa to the dermal structure. Mutations in the collagen type VII gene cause dystrophic epidermolysis bullosa with prominent skin ulcer and scar formation [31, 32]. These severe EBs usually occur in patients with homozygous mutation or compound heterozygous mutations. A heterozygous mutation, the same mutation but which harbors on only one allele of the gene, causes a milder form of EB, leading to the development of nodular prurigo-like lesions or scar formations in autosomal dominant type dystrophic EB or development of palmoplantar keratoderma with alopecia and dental deformation in autosomal dominant type junctional EB. A

*Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

### **Figure 3.**

*The structure of hemidesmosome. a) Electron microscopy of hemidesmosomes and basal lamina of a normal human subject. b) Schematic view of a hemidesmosome structure. Plectin forms a platform where keratin filaments and hemidesmosomal proteins bind, crosslinking keratin filaments with integrin beta4. Transmembrane protein bullous pemphigoid antigen 1 (BP180) connects hemidesmosomes to laminin 332, a component of the lamina densa. Bullous pemphigoid antigen 2 (BP230) is an intra-cytoplasmic protein that composes the hemidesmosome from inside the cells.*

recent study revealed that mutations in desmoplakin cause lethal acantholytic epidermolysis bullosa [33].

### **5. Skin barrier dysfunction in diseases**

Atopic dermatitis patients present decreased filaggrin and ceramide contents in their cornified layers, along with decreased skin barrier function [34]. This dysfunctional barrier allows allergens to penetrate the skin, thus, resulting in sensitization to environmental allergens [35]. Peanut allergies are often observed in infants of families that consume large amounts of peanut and have detectable levels of peanut debris in the surrounding environment [36]. Exercise-induced food allergy also develops in relation to filaggrin mutation [37]. A previous study has shown that infants with frequent emollient hydration of skin showed a lower rate of bronchial asthma development compared to babies without emollient hydration of skin, indicating the importance of the skin barrier functioning in maintaining overall health and stable homeostasis [38]. **Figure 4** illustrates the epidermal structure with barrier proteins.

Mutations in filaggrin and protease inhibitors can cause atopic dermatitis. Netherton syndrome is caused by a mutation in the serine protease inhibitor KAZAL type5 (*SPINK5*), which results in atopic dermatitis-like skin eruption [39]. Nagashima-type PPK is caused by a mutation in *SERPINB7*, a serine protease inhibitor, with low-grade hyperkeratosis on the palms and soles, involving the backside of the fingers, toes, and a triangular lesion on the wrist. Some cases of Nagashima-type PPK also develop food allergies or atopic dermatitis [40]. Protease inhibitors are essential for stopping the catalyzing reaction by proteases, thus, protecting the skin barrier from over-degradation. The precise mechanisms underlying the development of atopic dermatitis or allergy in Nagashima-type PPK patients are not clear, but one theory is that proteinase activation receptors are potent pro-inflammatory

### **Figure 4.**

*The structure of epidermis and its adhesion molecules. a) Schematic view of epidermis structure and its adhesion molecules. Basal keratinocytes attach to basement membrane through hemidesmosomes, having keratins such as KRT5 and KRT14. Suprabasal keratinocytes start to produce KRT1 and KRT10 and attach to neighboring keratinocytes with desmosomes. Granular layer cells express KRT2 containing keratohyalin granules and attach to the neighboring cells with tight junctions, which also have desmosomes. Corneocytes lose nuclei and embed in lipid layers, connecting each other with corneodesmosomes. Cornified cell envelope develops when cells become corneal layer cells from granular layer cells. Adherence junctions exist from basal keratinocytes to granular layer keratinocytes. b) Cornified envelope development from its components. Filaggrin aggregates keratin filaments and involucrin, and other cornified envelope proteins gather to form a cornified cell envelope, upon catalysis by transglutaminase 1.*

molecules that react with proteinases to induce inflammation. Thus, protease inhibitors could be a therapeutic target for atopic dermatitis [41].

Lipid abnormalities could be another cause of atopic dermatitis, demonstrating the skin barrier dysfunction. A decrease in ceramide content of the cornified layer has been demonstrated in patients with atopic dermatitis, which is another cause of skin barrier dysfunction [42]. Ceramide constitutes almost 50% of the lipids in the corneal layer and is indispensable for skin barrier function. Mutations in genes involved in lipid metabolism are not known in atopic dermatitis, but gene metabolic diseases, such as Gauche disease and Nieman-Pick disease that are characterized by mutations in the glucocerebrosidase and sphingomyelin phosphodiesterase 1 gene, respectively, which are indispensable in ceramide synthesis, resulting in development of atopic dermatitis-like skin eruptions from early childhood. Abnormalities in lipid metabolism could be another cause of atopic dermatitis, which requires further investigation [43].

Skin barrier function is affected not only by genetic conditions but also by ordinary routines of daily life. People who often scrub too much during bathing, bathe for a long time period or very frequently, and especially those who scrub their skin with nylon towels or scrubbing brushes show very dry skin with small scales all over the body. These individuals often complain of severe itching, especially after bathing, often resulting in eczema development. Excessive use of detergent also causes barrier disruption by increasing the pH of the skin, resulting in enhanced enzymatic activity of proteinases in the cornified layers [44]. These lifestyle routines would exacerbate eczematous changes in individuals having a genetic predisposition that makes them more susceptible to barrier disruption.

Keratinocytes form not only mechanical barriers but also chemical or immunological barriers for humans. They express several antimicrobial peptides, such as cathelicidin, defensin, psoriasin, and various S100 proteins. These antimicrobial peptides prevent pathogenic microbes from colonizing the skin surface, thus

*Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

conferring resistance to microbial infections [45]. Certain conditions such as atopic dermatitis have decreased production of antimicrobial peptides, leaving the individuals more susceptible to bacterial or viral infections through the skin [46, 47]. Filaggrin mutations are at times the direct cause of barrier disruption, but T helper (Th)2-skewed immune conditions can be another cause too, as Th2 type cytokines cause a less differentiated state of keratinocytes thus resulting in lower production of antimicrobial molecules and barrier proteins [48]. Mutations in filaggrin also cause ichthyosis vulgaris, which often co-exists in atopic dermatitis patients. However, not all patients with atopic dermatitis have ichthyosis vulgaris and vice versa, even in the presence of filaggrin gene mutations [7]. Thus, the filaggrin mutation alone cannot explain the pathogenesis of atopic dermatitis.

Psoriasis is another major inflammatory skin disorder that shows hyperproduction of antimicrobial peptides in the epidermis induced by skewed Th17 populations thus making patients resistant to skin infections [49, 50]. Cathelicidin—one of the antimicrobial peptides, complexes with self RNA or DNA to induce the activation of myeloid dendritic cells and plasmacytoid dendritic cells, respectively. This activation further triggers psoriatic inflammation, thus creating a positive feedback loop in pathogenesis of psoriasis [51, 52]. Recent advancements in translational research produced many "biologics", which target inflammatory cytokines, such as IL-17, TNF, and IL-23, as a treatment option for psoriasis. These include anti-TNF antibodies (adalimumab [53], infliximab [54], certolizumab-pegol [55]), anti-IL-17 antibodies (secukinumab [56, 57], ixekizumab [58], brodalumab [59], bimekizumab [60]), anti-IL-12/23p40 antibody (ustekinumab [61, 62]), and anti-IL-23p19 antibodies (guselkumab [63], risankizumab [64, 65], thildrakizumab [66–69]). Janus kinases (JAKs) are important intracellular signaling molecules downstream of cytokine receptors [70]. They are also deeply involved in inflammation in psoriasis, and JAK inhibitors have been developed as therapeutic options in psoriasis [71–76].

Ichthyosis has also been shown to have a Th17-skewed immune balance [77], and Th17 is a potent inducer of antifungal immunity. However, ichthyosis patients often develop cutaneous superficial fungal infections [78, 79]. Taken together, this suggests that the immune imbalance by itself cannot explain the susceptibility to fungal infections, meanwhile also implicating the importance of proper functioning of the skin barrier to avoid superficial fungal infections.

### **6. Danger signals from keratinocytes**

As a barrier, keratinocytes respond to emergency conditions by releasing danger-associated molecular patterns (DAMPs) when acutely injured. IL-33 is one such emergency molecule, which resides in the nucleus in a steady-state, but is released when cells undergo necrosis to stimulate immune reactions [80]. IL-33 is a relatively recently identified member of the IL-1 family and functions mainly as a pro-inflammatory molecule, although under certain conditions, it can also work as an anti-inflammatory molecule. IL-1 alpha—the prototype of IL-1 family members, was identified as an alarmin several decades ago. The Koebner phenomenon in psoriasis is attributed to the release of IL-1 alpha from damaged keratinocytes, which induces psoriasis in regions after skin injury [81]. IL-1 alpha is an interesting cytokine that mainly functions as a soluble cytokine, but also shows a nuclear presence. It has been reported that IL-1 alpha repeatedly travels between the cytoplasm and nucleus, and is released into the extracellular space upon cell damage to provoke inflammation [82]. IL-33 has similar characteristics in that it resides in the nucleus too, is released during cell necrosis, and induces inflammation. IL-33, similar to IL-1 beta, is produced as a full-length pro-form. IL-33 pro-form is active, but even

more, activated when digested by neutrophil elastases or cathepsin. It is, however, inactivated when digested by caspases, unlike IL-1 beta, which is activated by caspases during activation of NRLP3 inflammasomes. ST2L—a receptor of IL-33, is expressed on Th2 cells, group 2 innate lymphoid cells, and regulatory T cells, and its soluble form—sST2, blocks the interaction of IL-33 with ST2L [83].

IL-33 exhibits both pro-inflammatory and anti-inflammatory roles. As a Th2 cytokine, it stimulates ST2L-expressing cells, including mast cells, Th2, and ILC2 cells. This enhances Th2 type inflammation by inducing expression of Th2 type cytokines, such as IL-5 and IL-13. However, upon Th1 or Th17 activation, IL-33 may attenuate pathological conditions by skewing Th2 type inflammation. The graft versus host disease (GVHD) reaction [84] was reported to be attenuated by IL-33, and experimental autoimmune encephalomyelitis showed reduction in response to IL-33 action [85]. Graft rejection in heart transplantation was reported to be attenuated by treatment with IL-33 [86]. IL-33, by inducing regulatory T cell function, was shown to induce immunosuppression [87]. UVB-induced immunosuppression too has been shown to be attributed with IL-33 [87]. Immune dysregulation in coronavirus infection is hypothesized to be caused by the IL-1 family member of cytokines [88]. IL-33 has also been shown to induce neutrophilic infiltration in several animal models and disease conditions, which may be interpreted as a pro-inflammatory effect [89].

IL-33 has dual nuclear and soluble cytokine forms. Nuclear IL-33 functions as a transcriptional regulator. In acute wound healing processes, IL-33 functions by attenuating inflammation by affecting the NF kappa B activity and enhancing wound healing [90]. On the other hand, IL-33 as a cytokine enhances immune reactions in decubitus ulcer models (unpublished). Both IL-33 and IL-1 alpha, when in the nucleus, bind to chromatin and are not released easily, thus, forming a reservoir for inflammatory signals. The regulation of nuclear or cytoplasmic localization of IL-33 is not clear but maybe dependent on its nuclear localization signal. Tsuda et al. [91] revealed that there are several different forms of splice variants of naturally occurring IL-33, of which expression is regulated by distinct promoters [92]. These splice variants should have distinct roles, which could regulate the pro- or antiinflammatory properties of IL-33.

In the steady-state, keratinocytes should remain silent as a constitutively active state could result in excessive inflammation, which in turn can harm the overall human health. Cultured keratinocytes usually require higher concentrations of cytokines to provoke inflammatory signals; for example, keratinocytes need TNF in the range of several ng/ml to produce inflammatory cytokines, while dendritic cells or lymphocytes require only several pg/ml of the same cytokine to produce an inflammatory effect to the same or even a greater extent [93, 94]. Keratinocytes by differentiating to cornified cells become resistant to environmental stimuli, such as UVB; i.e., they usually respond sensitively to UVB in monolayer culture, but they become resistant to UVB stimulation when they differentiate in 3D-culture [95]. Some chemokines, such as MIP3 alpha/CCL20 are produced more in suprabasal cells than from basal cells [96], but production of IL-1 receptor antagonist is enhanced when keratinocytes are differentiated [97], which may result in attenuation of inflammatory response in differentiated keratinocytes. IL-33 and IL-1 alpha, more clearly expressed in suprabasal cells [98], when in the nucleus bind to chromatin not to be released easily, thus forming the reservoir for inflammatory signals.

### **7. Conclusion**

Epidermal keratinocytes protect humans from the outer environment by forming an efficient mechanical, chemical, and antimicrobial barrier. Mutations *Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

in various molecules present in the keratinocyte can cause hereditary disorders. The keratinocyte structure is maintained by many structural molecules, including keratins, actin, microtubules, and associated proteins and adhesion molecules. The barrier function depends on these structural molecules, as well as other antimicrobial and immunological components, such as infiltrating or resident immune cells, such as lymphocytes, dendritic cells, and macrophages. At the same time, keratinocytes are resistant to stimulation in comparison to other cell types, such as lymphocytes and dendritic cells, as shown in some pieces of literature that they respond to the same stimuli with much fewer attitudes compared to immune cells. IL-33, an alarmin released during insults into the skin, works as an alarmin to provoke inflammation, but at the same time often attenuates inflammation by activating regulatory T cells and skewing Th2 mediated inflammation. This relative unresponsiveness and dual-faced character with pro- and anti-inflammatory properties would be the characteristics of keratinocytes, which cover the entire body by facing environmental stimuli all the time. Thus, the differentiation and structural characteristics of epidermal keratinocytes prevent the skin from hypersensitivity to environmental stimuli.

The mechanism of developing inflammatory conditions has been intensively investigated, but the mechanism by which the inflammation status returns to the steady-state, or how inflammatory status remains under control to prevent excessive inflammation in healthy humans has not been fully investigated.

A novel approach to maintaining healthy conditions would be unraveled when the mechanism of sequestrating inflammation and returning to normal steady-state condition is investigated. Epidermal keratinocytes are good candidates to investigate these mechanisms because they present both pro- and anti-inflammatory properties in vivo and in vitro.

### **Acknowledgements**

I thank all the members of our department for participating in clinical and basic research on patients.

### **Conflict of interest**

The authors declare no conflict of interest.

### **Author details**

Mayumi Komine1,2\*, Jin Meijuan1 , Miho Kimura-Sashikawa1 , Razib MD. Hossain1 , Tuba M. Ansary1 , Tomoyuki Oshio3 , Jitlada Meephansan4 , Hidetoshi Tsuda5 , Shin-ichi Tominaga2,6 and Mamitaro Ohtsuki1

1 Department of Dermatology, Jichi Medical University, Japan

2 Department of Biochemistry, Jichi Medical University, Japan

3 Ryukakusan, Co., Ltd., Japan

4 Division of Dermatology, Chulabhorn International College of Medicine, Thammasat University, Thailand

5 Division of Human Genetics, Center for Molecular Medicine, Jichi Medical University, Japan

6 Japan Association of Development of Community Medicine (JADECOM), Japan

\*Address all correspondence to: mkomine12@jichi.ac.jp

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

### **References**

[1] Blumenberg M, Tomić-Canić M. Human epidermal keratinocyte: Keratinization processes. EXS. 1997;**78**:1-29. DOI: 10.1007/978-3-0348- 9223-0\_1

[2] Bragulla HH, Homberger DG. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia. Journal of Anatomy. 2009;**214**(4):516- 559. DOI: 10.1111/j.1469-7580. 2009.01066.x

[3] Oji V, Tadini G, Akiyama M, Blanchet Bardon C, Bodemer C, Bourrat E, et al. Revised nomenclature and classification of inherited ichthyoses: Results of the first ichthyosis consensus conference in Sorèze 2009. Journal of the American Academy of Dermatology. 2010;**63**(4): 607-641. DOI: 10.1016/j.jaad.2009. 11.020

[4] Barker JN, Palmer CN, Zhao Y, Liao H, Hull PR, Lee SP, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. The Journal of Investigative Dermatology. 2007;**127**(3):564-567. DOI: 10.1038/ sj.jid.5700587

[5] Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, Pembrey M, et al. The burden of disease associated with filaggrin mutations: A population-based longitudinal birth cohort study. The Journal of Allergy and Clinical Immunology. 2008;**121**(4):872-7.e9. DOI: 10.1016/j.jaci.2008.01.026

[6] Kezic S, O'Regan GM, Lutter R, Jakasa I, Koster ES, Saunders S, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. The Journal of Allergy and Clinical

Immunology. 2012;**129**(4):1031-9.e1. DOI: 10.1016/j.jaci.2011.12.989

[7] WH ML. Filaggrin failure - from ichthyosis vulgaris to atopic eczema and beyond. The Journal of Dermatology. 2016;**175**(Suppl. 2):4-7. DOI: 10.1111/ bjd.14997

[8] Eckert RL, Sturniolo MT, Broome AM, Ruse M, Rorke EA. Transglutaminases in epidermis. Progress in Experimental Tumor Research. 2005;**38**:115-124. DOI: 10.1159/000084236

[9] Richard G, Brown N, Rouan F, Van der Schroeff JG, Bijlsma E, Eichenfield LF, et al. Genetic heterogeneity in erythrokeratodermia variabilis: Novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. The Journal of Investigative Dermatology. 2003;**120**(4):601-609. DOI: 10.1046/j. 1523-1747.2003.12080.x

[10] Ishida-Yamamoto A, Kato H, Kiyama H, Armstrong DK, Munro CS, Eady RA, et al. Mutant loricrin is not crosslinked into the cornified cell envelope but is translocated into the nucleus in loricrin keratoderma. The Journal of Investigative Dermatology. 2000;**115**(6):1088-1094. DOI: 10.1046/j. 1523-1747.2000.00163.x

[11] Ishida-Yamamoto A, Iizuka H. Structural organization of cornified cell envelopes and alterations in inherited skin disorders. Experimental Dermatology. 1998;**7**(1):1-10. DOI: 10.1111/j.1600-0625.1998. tb00295.x

[12] Epstein EH Jr, Leventhal ME. Steroid sulfatase of human leukocytes and epidermis and the diagnosis of recessive X-linked ichthyosis. The Journal of Clinical Investigation. 1981;**67**(5):1257-1262. DOI: 10.1172/ jci110153

[13] Mazereeuw-Hautier J, Bitoun E, Chevrant-Breton J, Man SY, Bodemer C, Prins C, et al. Keratitis-ichthyosisdeafness syndrome: Disease expression and spectrum of connexin 26 (GJB2) mutations in 14 patients. The Journal of Dermatology. 2007;**156**(5):1015-1019. DOI: 10.1111/j.1365-2133.2007.07806.x

[14] Raghunath M, Tontsidou L, Oji V, Aufenvenne K, Schürmeyer-Horst F, Jayakumar A, et al. SPINK5 and Netherton syndrome: Novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. The Journal of Investigative Dermatology. 2004;**123**(3): 474-483. DOI: 10.1111/j.0022-202X. 2004.23220.x

[15] Rizzo WB. Sjogren-Larsson syndrome: Molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Molecular Genetics and Metabolism. 2007;**90**(1):1-9. DOI: 10.1016/j. ymgme.2006.08.006

[16] Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. The Journal of Investigative Dermatology. 2001;**116**(5):633-640. DOI: 10.1046/j. 1523-1747.2001.01327.x

[17] Corden LD, McLean WH. Human keratin diseases: Hereditary fragility of specific epithelial tissues. Experimental Dermatology. 1996;**5**(6):297-307. DOI: 10.1111/j.1600-0625.1996. tb00133.x

[18] Smith FJ, Liao H, Cassidy AJ, Stewart A, Hamill KJ, Wood P, et al. The genetic basis of pachyonychia congenita. The Journal of Investigative Dermatology. Symposium Proceedings. 2005;**10**(1):21-30. DOI: 10.1111/j. 1087-0024.2005.10204.x

[19] Richard G, De Laurenzi V, Didona B, Bale SJ, Compton JG. Keratin 13 point mutation underlies the hereditary

mucosal epithelial disorder white sponge nevus. Nature Genetics. 1995;**11**(4):453-455. DOI: 10.1038/ ng1295-453

[20] Jang KH, Yoon HN, Lee J, Yi H, Park SY, Lee SY, et al. Liver diseaseassociated keratin 8 and 18 mutations modulate keratin acetylation and methylation. The FASEB Journal. 2019;**33**(8):9030-9043. DOI: 10.1096/ fj.201800263RR

[21] Zhou Q, Ji X, Chen L, Greenberg HB, Lu SC, Omary MB. Keratin mutation primes mouse liver to oxidative injury. Hepatology. 2005;**41**(3):517-525. DOI: 10.1002/ hep.20578

[22] Ku NO, Gish R, Wright TL, Omary MB. Keratin 8 mutations in patients with cryptogenic liver disease. The New England Journal of Medicine. 2001;**344**(21):1580-1587. DOI: 10.1056/ NEJM200105243442103

[23] Yancey KB. Adhesion molecules. II: Interactions of keratinocytes with epidermal basement membrane. The Journal of Investigative Dermatology. 1995;**104**(6):1008-1014. DOI: 10.1111/ 1523-1747.ep12606244

[24] Amagai M. Adhesion molecules. I: Keratinocyte-keratinocyte interactions; cadherins and pemphigus. The Journal of Investigative Dermatology. 1995;**104**(1):146-152. DOI: 10.1111/1523- 1747.ep12613668

[25] Indra I, Hong S, Troyanovsky R, Kormos B, Troyanovsky S. The adherens junction: A mosaic of cadherin and nectin clusters bundled by actin filaments. The Journal of Investigative Dermatology. 2013;**133**(11):2546-2554. DOI: 10.1038/jid.2013.200

[26] Matsui T, Amagai M. Dissecting the formation, structure, and barrier function of the stratum corneum. International Immunology.

*Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

2015;**27**(6):269-280. DOI: 10.1093/ intimm/dxv013

[27] Kitajima Y. 150(th) anniversary series: Desmosomes and autoimmune disease, perspective of dynamic desmosome remodeling and its impairments in pemphigus. Cell Communication & Adhesion. 2014;**21**(6):269-280. DOI: 10.3109/ 15419061.2014.943397

[28] Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. The Journal of Dermatology. 2020;**183**(4): 614-627. DOI: 10.1111/bjd.18921

[29] Condrat I, He Y, Cosgarea R, Has C. Junctional epidermolysis bullosa: Allelic heterogeneity and mutation stratification for precision medicine. Front Med (Lausanne). 2019;**5**:363. DOI: 10.3389/fmed.2018.00363

[30] Chung HJ, Uitto J. Epidermolysis bullosa with pyloric atresia. Dermatologic Clinics. 2010;**28**(1):43-54. DOI: 10.1016/j.det.2009.10.005

[31] Iinuma S, Aikawa E, Tamai K, Fujita R, Kikuchi Y, Chino T, et al. Transplanted bone marrow-derived circulating PDGFRalpha+ cells restore type VII collagen in a recessive dystrophic epidermolysis bullosa mouse skin graft. Journal of Immunology. 2015;**194**(4):1996-2003. DOI: 10.4049/ jimmunol.1400914

[32] Tamai K, Uitto J. Stem cell therapy for epidermolysis bullosa-does it work? The Journal of Investigative Dermatology. 2016;**136**(11):2119-2121. DOI: 10.1016/j.jid.2016.07.004

[33] McGrath JA, Bolling MC, Jonkman MF. Lethal acantholytic epidermolysis bullosa. Dermatologic Clinics. 2010;**28**(1):131-135. DOI: 10.1016/j.det.2009.10.015

[34] Horimukai K, Morita K, Narita M, Kondo M, Kitazawa H, Nozaki M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. The Journal of Allergy and Clinical Immunology. 2014;**134**(4):824- 830.e6. DOI: 10.1016/j.jaci.2014.07.060

[35] Komine M. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: Keratinocytes in atopic dermatitis: Their pathogenic involvement. Journal of Pharmacological Sciences. 2009;**110**(3): 260-264. DOI: 10.1254/jphs.09r06fm

[36] Natsume O, Ohya Y. Recent advancement to prevent the development of allergy and allergic diseases and therapeutic strategy in the perspective of barrier dysfunction. Allergology International. 2018; **67**(1):24-31. DOI: 10.1016/j.alit. 2017.11.003

[37] Mizuno O, Nomura T, Ohguchi Y, Suzuki S, Nomura Y, Hamade Y, et al. Loss-of-function mutations in the gene encoding filaggrin underlie a Japanese family with food-dependent exerciseinduced anaphylaxis. Journal of the European Academy of Dermatology and Venereology. 2015;**29**(4):805-808. DOI: 10.1111/jdv.12441

[38] Yamamoto-Hanada K, Kobayashi T, Williams HC, Mikami M, Saito-Abe M, Morita K, et al. Early aggressive intervention for infantile atopic dermatitis to prevent development of food allergy: A multicenter, investigator-blinded, randomized, parallel group controlled trial (PACI study)-protocol for a randomized controlled trial. Clin Transl Allergy. 2018;**8**:47. DOI: 10.1186/s13601-018- 0233-8

[39] Hovnanian A. Netherton syndrome: Skin inflammation and allergy by loss of protease inhibition. Cell and Tissue Research. 2013;**351**(2):289-300. DOI: 10.1007/s00441-013-1558-1

[40] Yamauchi A, Kubo A, Ono N, Shiohama A, Tsuruta D, Fukai K. Three cases of Nagashima-type palmoplantar keratosis were associated with atopic dermatitis: A diagnostic pitfall. The Journal of Dermatology. 2018;**45**(5): e112-e113. DOI: 10.1111/1346-8138. 14152

[41] Smith PK, Harper JI. Serine proteases, their inhibitors and allergy. Allergy. 2006;**61**(12):1441-1447. DOI: 10.1111/j.1398-9995.2006.01233.x

[42] Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A. Decreased level of ceramides in stratum corneum of atopic dermatitis: An etiologic factor in atopic dry skin? The Journal of Investigative Dermatology. 1991;**96**(4): 523-526. DOI: 10.1111/1523-1747. ep12470233

[43] Teranishi Y, Kuwahara H, Ueda M, Takemura T, Kusumoto M, Nakamura K, et al. Sphingomyelin Deacylase, the enzyme involved in the pathogenesis of atopic dermatitis, is identical to the beta-subunit of acid ceramidase. International Journal of Molecular Sciences. 2020;**21**(22):8789. DOI: 10.3390/ijms21228789

[44] Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, Moustafa M, MacGowan A, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions. The Journal of Allergy and Clinical Immunology. 2006;**118**(1):3-21; quiz 22-3. DOI: 10.1016/j.jaci.2006.04.042

[45] Takahashi T, Gallo RL. The critical and multifunctional roles of antimicrobial peptides in dermatology. Dermatologic Clinics. 2017;**35**(1):39-50. DOI: 10.1016/j.det.2016.07.006

[46] Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic

dermatitis. The New England Journal of Medicine. 2002;**347**(15):1151-1160. DOI: 10.1056/NEJMoa021481

[47] Smits JPH, Ederveen THA, Rikken G, van den Brink NJM, van Vlijmen-Willems IMJJ, Boekhorst J, et al. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHRdependent induction of antimicrobial peptides. The Journal of Investigative Dermatology. 2020;**140**(2):415-424.e10. DOI: 10.1016/j.jid.2019.06.142

[48] Rangel SM, Paller AS. Bacterial colonization, overgrowth, and superinfection in atopic dermatitis. Clinics in Dermatology. 2018;**36**(5):641- 647. DOI: 10.1016/j.clindermatol. 2018.05.005

[49] Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. The Journal of Dermatology. 2012;**39**(3):225-230. DOI: 10.1111/j. 1346-8138.2011.01483.x

[50] Chiricozzi A, Nograles KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM, et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One. 2014;**9**(2):e90284. DOI: 10.1371/journal. pone.0090284

[51] Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;**449**(7162):564- 569. DOI: 10.1038/nature06116

[52] Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells via TLR7 and TLR8. The Journal of Experimental Medicine. 2009;**206**(9): 1983-1994. DOI: 10.1084/jem.20090480

[53] Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy *Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. Journal of the American Academy of Dermatology. 2012;**66**(2):241-251. DOI: 10.1016/j.jaad.2010.12.005

[54] Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet. 2001;**357**(9271):1842-1847. DOI: 10.1016/s0140-6736(00)04954-0

[55] Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: Results of a phase II randomized, placebo-controlled trial with a re-treatment extension. The British Journal of Dermatology. 2012;**167**(1): 180-190. DOI: 10.1111/j.1365-2133. 2012.10941.x

[56] Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, et al. Secukinumab efficacy and safety in Japanese patients with moderate-tosevere plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. The Journal of Dermatology. 2014;**41**(12): 1039-1046. DOI: 10.1111/1346-8138. 12668

[57] Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. The New England Journal of Medicine. 2014;**371**(4):32638. DOI: 10.1056/ NEJMoa1314258

[58] Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. The New England Journal of Medicine. 2016;**375**(4):345-356. DOI: 10.1056/ NEJMoa1512711

[59] Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. Journal of the American Academy of Dermatology. 2014;**71**(6):1183-1190.e3. DOI: 10.1016/j. jaad.2014.08.039

[60] Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebocontrolled, phase 2b extension study. Journal of the American Academy of Dermatology. 2020;**83**(5):1367-1374. DOI: 10.1016/j.jaad.2020.05.105

[61] Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;**371**(9625): 1665-1674. DOI: 10.1016/S0140-6736 (08)60725-4

[62] Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;**371**(9625): 1675-1684. DOI: 10.1016/S0140-6736 (08)60726-6

[63] Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III,

double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology. 2017;**76**(3):405-417. DOI: 10.1016/j.jaad.2016.11.041

[64] Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumabcontrolled phase 3 trials. Lancet. 2018;**392**(10148):650-661. DOI: 10.1016/ S0140-6736(18)31713-6

[65] Ohtsuki M, Fujita H, Watanabe M, Suzaki K, Flack M, Huang X, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial. The Journal of Dermatology. 2019;**46**(8):686-694. DOI: 10.1111/1346-8138.14941

[66] Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials. Lancet. 2017;**390**(10091):276-288

[67] Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: Pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. The British Journal of Dermatology. 2020;**182**(3):605-617. DOI: 10.1111/bjd.18232

[68] Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1). The

Journal of Dermatology. 2021;**48**(6):844-852. DOI: 10.1111/ 1346-8138.15763

[69] Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1). The Journal of Dermatology. 2021;**48**(6):853- 863. DOI: 10.1111/1346-8138.15789

[70] Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nature Reviews Rheumatology. 2022:1-13. DOI: 10.1038/s41584-021-00726-8

[71] Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials. The British Journal of Dermatology. 2015;**173**(4):949-961. DOI: 10.1111/bjd.14018

[72] Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. The Journal of Dermatology. 2016;**43**(8):869-880. DOI: 10.1111/1346-8138.13258

[73] Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. The British Journal of Dermatology. 2016;**174**(6):1266-1276. DOI: 10.1111/ bjd.14403

[74] Mease PJ, Lertratanakul A, Papp KA, van den Bosch FE, Tsuji S, *Keratinocytes in Skin Disorders: The Importance of Keratinocytes as a Barrier DOI: http://dx.doi.org/10.5772/intechopen.103732*

Dokoupilova E, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study. Rheumatol Ther. 2021;**8**(2):903-919. DOI: 10.1007/s40744-021-00305-z

[75] Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderateto-severe psoriasis: Phase II, randomized, double-blind, placebocontrolled study. The British Journal of Dermatology. 2018;**179**(1):54-62. DOI: 10.1111/bjd.16004

[76] Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: Focus on selective TYK2 inhibitors. Drugs. 2020;**80**(4):341-352. DOI: 10.1007/s40265-020-01261-8

[77] Malik K, He H, Huynh TN, Tran G, Mueller K, Doytcheva K, et al. Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature. The Journal of Allergy and Clinical Immunology. 2019;**143**(2):604-618. DOI: 10.1016/j.jaci.2018.03.021

[78] Sheetz K, Lynch PJ. Ichthyosis and dermatophyte fungal infection. Journal of the American Academy of Dermatology. 1991;**24**(2 Pt 1):321. DOI: 10.1016/s0190-9622(08)80637-8

[79] Schøsler L, Andersen LK, Arendrup MC, Sommerlund M. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatric Dermatology. 2018;**35**(2):259- 260. DOI: 10.1111/pde.13411

[80] Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunological Reviews. 2018;**281**(1):154-168. DOI: 10.1111/ imr.12619

[81] Groves RW, Sherman L, Mizutani H, Dower SK, Kupper TS. Detection of interleukin-1 receptors in the human epidermis induction of the type II receptor after organ culture and psoriasis. The American Journal of Pathology. 1994;**145**(5):1048-1056

[82] Ross R, Grimmel J, Goedicke S, Möbus AM, Bulau AM, Bufler P, et al. Analysis of the nuclear localization of interleukin-1 family cytokines by flow cytometry. Journal of Immunological Methods. 2013;**387**(1-2):219-227. DOI: 10.1016/j.jim.2012.10.017

[83] Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. The Journal of Biological Chemistry. 2007;**282**(36):26369-26380. DOI: 10.1074/jbc.M704916200

[84] Matta BM, Reichenbach DK, Zhang X, Mathews L, Koehn BH, Dwyer GK, et al. Peri-alloHCT IL-33 administration expands the recipient T-regulatory cells that protect mice against acute GVHD. Blood. 2016; **128**(3):427-439. DOI: 10.1182/blood-2015-12-684142

[85] Jiang HR, Milovanović M, Allan D, Niedbala W, Besnard AG, Fukada SY, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. European Journal of Immunology. 2012;**42**(7):1804-1814. DOI: 10.1002/eji.201141947

[86] Matta BM, Lott JM, Mathews LR, Liu Q, Rosborough BR, Blazar BR, et al. IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. Journal of Immunology. 2014;**193**(8):4010-4020. DOI: 10.4049/jimmunol.1400481

[87] Byrne SN, Beaugie C, O'Sullivan C, Leighton S, Halliday GM. The

immune-modulating cytokine and endogenous Alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. The American Journal of Pathology. 2011;**179**(1):211-222. DOI: 10.1016/j. ajpath.2011.03.010

[88] Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy. Journal of Biological Regulators and Homeostatic Agents. 2020;**34**(1):9- 14. DOI: 10.23812/20-Editorial-Kritas

[89] Alves-Filho JC, Sônego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nature Medicine. 2010;**16**(6):708-712. DOI: 10.1038/nm.2156

[90] Oshio T, Komine M, Tsuda H, Tominaga SI, Saito H, Nakae S, et al. Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. Journal of Dermatological Science. 2017;**85**(2):106- 114. DOI: 10.1016/j.jdermsci.2016.10.008

[91] Tsuda H, Komine M, Karakawa M, Etoh T, Tominaga S, Ohtsuki M. Novel splice variants of IL-33: Differential expression in normal and transformed cells. The Journal of Investigative Dermatology. 2012;**132**(11):2661-2664. DOI: 10.1038/jid.2012.180

[92] Tsuda H, Komine M, Tominaga SI, Ohtsuki M. Identification of the promoter region of human IL-33 responsive to induction by IFNγ. Journal of Dermatological Science. 2017;**85**(2): 137-140. DOI: 10.1016/j.jdermsci.2016. 11.002

[93] Chung JH, Youn SH, Koh WS, Eun HC, Cho KH, Park KC, et al. Ultraviolet B irradiation-enhanced interleukin (IL)-6 production and mRNA expression are mediated by IL-1 alpha in cultured human keratinocytes. The Journal of Investigative Dermatology. 1996;**106**(4):715-720. DOI: 10.1111/1523-1747.ep12345608

[94] Tosato G, Jones KD. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood. 1990;**75**(6):1305-1310

[95] Corsini E, Sangha N, Feldman SR. Epidermal stratification reduces the effects of UVB (but not UVA) on keratinocyte cytokine production and cytotoxicity. Photodermatology, Photoimmunology & Photomedicine. 1997;**13**(4):147-152. DOI: 10.1111/j.1600- 0781.1997.tb00219.x

[96] Tohyama M, Shirakara Y, Yamasaki K, Sayama K, Hashimoto K. Differentiated keratinocytes are responsible for TNF-alpha regulated production of macrophage inflammatory protein 3alpha/CCL20, a potent chemokine for Langerhans cells. Journal of Dermatological Science. 2001;**27**(2):130-139. DOI: 10.1016/ s0923-1811(01)00127-x

[97] Bigler CF, Norris DA, Weston WL, Arend WP. Interleukin-1 receptor antagonist production by human keratinocytes. The Journal of Investigative Dermatology. 1992;**98**(1): 38-44. DOI: 10.1111/1523-1747. ep12494196

[98] Meephansan J, Komine M, Tsuda H, Karakawa M, Tominaga S, Ohtsuki M. Expression of IL-33 in the epidermis: The mechanism of induction by IL-17. Journal of Dermatological Science. 2013;**71**(2):107-114. DOI: 10.1016/j. jdermsci.2013.04.014 Epub 2013 Apr 19

## *Edited by Mayumi Komine*

Keratinocytes have various functions to maintain epidermal homeostasis. Many inflammatory skin diseases can develop due to suppressed or defective antiinflammatory properties of keratinocytes. This book discusses the structural, biological, and molecular aspects of keratinocytes. Chapters discuss keratins and attachment molecules and their importance in maintaining epidermal homeostasis, skin diseases such as psoriasis and atopic dermatitis, and aging and skin regeneration.

Published in London, UK © 2022 IntechOpen © J.E L. C. MARTIN & J. E. G.-M. MUZQUIZ / iStock

Keratinocyte Biology - Structure and Function in the Epidermis

Keratinocyte Biology

Structure and Function in the Epidermis

*Edited by Mayumi Komine*